Allergan plc Ordinary Shares (NYSE:AGN) has been downgraded to Hold in a report by Cantor Fitzgerald today.
- Updated: September 21, 2016
Cantor Fitzgerald has downgraded Allergan plc Ordinary Shares (NYSE:AGN) to Hold in a report released on 09/21/2016.
Previously on Friday August 19, 2016, Mizuho reported about Allergan plc Ordinary Shares (NYSE:AGN) raised the target price from $248.00 to $318.00. At the time, this indicated a possible upside of 0.25%.
Yesterday Allergan plc Ordinary Shares (NYSE:AGN) traded -0.11% lower at $235.01. AGN’s 50-day average is $245.54 and its two hundred day average is $243.04. With the last close down -1.90% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 3,391,132 shares of AGN traded, up from an avg. volume of 3,089,300
With a market cap of $0, Allergan plc Ordinary Shares has 52 week low of $195.50 and a 52 week high of $322.68 with a P/E ratio of 22.70 .
Also covering Allergan plc Ordinary Shares's price target, a total of 16 analysts have released a ratings update on AGN. The one year target is $293.75 with seven equity analysts rating the stock a strong buy, 11 brokerages rating the company a buy, two brokers rating the stock a hold, 0 analysts rating the company a underperform, and lastly 0 firms rating the stock a sell.
About Allergan plc Ordinary Shares (NYSE:AGN)
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, and medical aesthetics, as well as dermatology and plastic surgery. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. Allergan plc also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physiciansÂ’ offices. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.